Pretreatment assessment of hepatocellular carcinoma: Expert consensus statement

HPB

Volumn 12, Issue 5, 2010, Pages 289-299

  Vauthey, Jean Nicolas ^a   Dixon, Elijah ^b   Abdalla, Eddie K ^a   Helton, W Scott ^c   Pawlik, Timothy M ^d   Taouli, Bachir ^e   Brouquet, Antoine ^a   Adams, Reid B ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c HOSPITAL OF SAINT RAPHAEL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Chemoembolization; Chemotherapy; Consensus conference; Hepatocellular cancer; Hepatoma; Liver function; Portal vein embolisation; Radiotherapy; Staging; Surgery

Indexed keywords

VASCULOTROPIN;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSENSUS; DIAGNOSTIC ACCURACY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PORTAL VEIN; PREOPERATIVE EVALUATION; PROGNOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOLUMETRY;

EID: 77953550870     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00181.x     Document Type: Conference Paper

References (99)

1. Bruix J, Llovet JM. (2004) Prognostic prediction on HCC: Did anybody expect it to be easy? Hepatology 39:551-552.
2. Okuda K. (2002) Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 17:401-405.
3. Llovet JM, Bru C, Bruix J. (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-338.
4. Pons F, Varela M, Llovet JM. (2005) Staging systems in hepatocellular carcinoma. HPB (Oxford) 7:35-41.
5. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430.
6. Farinati F, Sergio A, Baldan A, Giacomin A, Di Nolfo MA, Del Poggio P et al. (2009) Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 9:33.
7. Helton W, Strasberg S. (2003) AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: rationale and overview of the conference. HPB (Oxford) 5:238-242.
8. Fleming ID. (2001) AJCC/TNM cancer staging, present and future. J Surg Oncol 77:233-236.
9. Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. (2003) AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB 5:243-250.
10. Lo CM, Fan ST, Liu CL, Poon RT, Lam CM, Yuen WK et al. (2000) Determining resectability for hepatocellular carcinoma: the role of laparoscopy and laparoscopic ultrasonography. J Hepatobiliary Pancreat Surg 7:260-264.
11. Delbeke D, Martin WH. (2005) Update of PET and PET/CT for hepatobiliary and pancreatic malignancies. HPB (Oxford) 7:166-179.
12. Nathan H, Mentha G, Marques HP, Capussotti L, Majno P, Aldrighetti L et al. (2009) Comparative performances of staging systems for early hepatocellular carcinoma. HPB (Oxford) 11:382-390.
13. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G et al. (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44:723-731.
14. Wildi S, Pestalozzi BC, McCormack L, Clavien PA. (2004) Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 91:400-408.
15. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41:707-716.
16. Vauthey JN, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G et al. (2007) Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 204:1016-1027.
17. Nanashima A, Sumida Y, Morino S, Yamaguchi H, Tanaka K, Shibasaki S et al. (2004) The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol 30:765-770.
18. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B et al. (2005) Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54:411-418.
19. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. (2007) Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 245:909-922.
20. Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D'Onofrio M et al. (2008) Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 103:597-604.
21. Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC, Liu YC et al. (2007) Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. Eur J Surg Oncol 33:480-487.
22. Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL et al. (2009) Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method-analysis of 2010 Taiwanese patients. Eur J Cancer 45:1630-1639.
23. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N et al. (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527-1536.
24. Nathan H, Schulick RD, Choti MA, Pawlik TM. (2009) Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249:799-805.
25. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL et al. (2008) Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 19:1117-1126.
26. Liver (including intrahepatic bile ducts). In: Greene FL, Page DL, Fleming ID et al., eds. American Joint Committee on Cancer Staging Manual. New York, NY: Springer-Verlag, 2002:131-144.
27. Kaibori M, Ishizaki M, Saito T, Matsui K, Kwon AH, Kamiyama Y. (2009) Risk factors and outcome of early recurrence after resection of small hepatocellular carcinomas. Am J Surg 198:39-45.
28. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699.
29. Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, Visintainer P et al. (2008) Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol 15:1383-1391.
30. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al. (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394-1403.
31. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J et al. (2008) Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 14:1107-1115.
32. Yao FY, Kerlan RK, Jr., Hirose R, Davern TJ, 3rd, Bass NM, Feng S et al. (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48:819-827.
33. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC et al. (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9:416-423.
34. Jonas S, Al-Abadi H, Benckert C, Thelen A, Hippler-Benscheid M, Saribeyoglu K et al. (2009) Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 250:1008-1013.
35. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:1835-1845.
36. Wong JB, McQuillan GM, McHutchison JG, Poynard T. (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90:1562-1569.
37. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. (2007) Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 14:107-115.
38. Iannaccone R, Laghi A, Catalano C, Rossi P, Mangiapane F, Murakami T et al. (2005) Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 234:460-467.
39. Laghi A, Iannaccone R, Rossi P, Carbone I, Ferrari R, Mangiapane F et al. (2003) Hepatocellular carcinoma: detection with triple-phase multidetector row helical CT in patients with chronic hepatitis. Radiology 226:543-549.
40. Fazel R, Krumholz HM, Wang Y, Ross JS, Chen J, Ting HH et al. (2009) Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 361:849-857.
41. Kim SK, Lim JH, Lee WJ, Kim SH, Choi D, Lee SJ et al. (2002) Detection of hepatocellular carcinoma: comparison of dynamic three-phase computed tomography images and four-phase computed tomography images using multidetector row helical computed tomography. J Comput Assist Tomogr 26:691-698.
42. Murakami T, Kim T, Kawata S, Kanematsu M, Federle MP, Hori M et al. (2003) Evaluation of optimal timing of arterial phase imaging for the detection of hypervascular hepatocellular carcinoma by using triple arterial phase imaging with multidetector-row helical computed tomography. Invest Radiol 38:497-503.
43. Rofsky NM, Lee VS, Laub G, Pollack MA, Krinsky GA, Thomasson D et al. (1999) Abdominal MR imaging with a volumetric interpolated breath-hold examination. Radiology 212:876-884.
44. Lee VS, Hecht EM, Taouli B, Chen Q, Prince K, Oesingmann N. (2007) Body and cardiovascular MR imaging at 3.0 T. Radiology 244:692-705.
45. Barth MM, Smith MP, Pedrosa I, Lenkinski RE, Rofsky NM. (2007) Body MR imaging at 3.0 T: understanding the opportunities and challenges. Radiographics 27:1445-1462; discussion 1462-11444
46. Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, Picaud G et al. (2001) Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 25:327-336.
47. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R et al. (2003) MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38:1034-1042.
48. Kim HJ, Kim KW, Byun JH, Won HJ, Shin YM, Kim PN et al. (2006) Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. AJR Am J Roentgenol 186:1059-1066.
49. Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Chon SB et al. (2006) Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 186:149-157.
50. Frericks BB, Loddenkemper C, Huppertz A, Valdeig S, Stroux A, Seja M et al. (2009) Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 193:1053-1060.
51. Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N. (2009) Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol 50:709-715.
52. Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675-1681.
53. Tamada T, Ito K, Sone T, Yamamoto A, Yoshida K, Kakuba K et al. (2009) Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging 29:636-640.
54. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. (2008) Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 43:504-511.
55. Hammerstingl R, Huppertz A, Breuer J, Balzer T, Blakeborough A, Carter R et al. (2008) Diagnostic efficacy of gadoxetic acid (Primovist)- enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18:457-467.
56. Dohr O, Hofmeister R, Treher M, Schweinfurth H. (2007) Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol 42:830-841.
57. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. (2007) MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 6:43-52.
58. Zizka J, Klzo L, Ferda J, Mrklovsky M, Bukac J. (2007) Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol 62:186-191.
59. Vogl TJ, Kummel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T et al. (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59-67.
60. Jung G, Breuer J, Poll LW, Koch JA, Balzer T, Chang S et al. (2006) Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 47:15-23.
61. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D. (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17:2519-2530.
62. Bhartia B, Ward J, Guthrie JA, Robinson PJ. (2003) Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am J Roentgenol 180:577-584.
63. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193:1044-1052.
64. Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E et al. (2008) Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135:32-40.
65. Hagiwara M, Rusinek H, Lee VS, Losada M, Bannan MA, Krinsky GA et al. (2008) Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 246:926-934.
66. Chandarana H, Lim RP, Jensen JH, Hajdu CH, Losada M, Babb JS et al. (2009) Hepatic iron deposition in patients with liver disease: preliminary experience with breath-hold multiecho T2*-weighted sequence. AJR Am J Roentgenol 193:1261-1267.
67. Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. (1986) Preoperative portal vein embolization for hepatocellular carcinoma.World J Surg 10:803-808.
68. Uesaka K, Nimura Y, Nagino M. (1996) Changes in hepatic lobar function after right portal vein embolization. An appraisal by biliary indocyanine green excretion. Ann Surg 223:77-83.
69. Hirai I, Kimura W, Fuse A, Suto K, Urayama M. (2003) Evaluation of preoperative portal embolization for safe hepatectomy, with special reference to assessment of nonembolized lobe function with 99mTc-GSA SPECT scintigraphy. Surgery 133:495-506.
70. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C et al. (2000) Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 127:512-519.
71. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V et al. (2003) Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237:208-217.
72. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K et al. (1997) Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 26:1176-1181.
73. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO et al. (2009) Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 145:399-405.
74. Shirabe K, Shimada M, Gion T, Hasegawa H, Takenaka K, Utsunomiya T et al. (1999) Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 188:304-309.
75. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J et al. (2008) Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 247:49-57.
76. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. (2002) Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 137:675- 680; discussion 680-1671
77. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. (2007) Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 94:1386-1394.
78. Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC,Wallace MJ et al. (2009) Three Hundred and One Consecutive Extended Right Hepatectomies: Evaluation of Outcome Based on Systematic Liver Volumetry. Ann Surg
79. Vauthey JN, Pawlik TM, Abdalla EK, Arens JF, Nemr RA, Wei SH et al. (2004) Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 239:722-730; discussion 730-1722
80. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D et al. (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657; discussion 657-1648
81. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A et al. (2000) Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 231:480-486.
82. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y et al. (2004) Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 139:766-774.
83. Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. (2006) Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 93:1091-1098.
84. Bedossa P, Dargere D, Paradis V. (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38:1449-1457.
85. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K et al. (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134:1908-1916.
86. Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M et al. (2005) Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9:1207-1215; discussion 1215.
87. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G et al. (2006) Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 12:966-971.
88. Capussotti L, Ferrero A, Vigano L, Muratore A, Polastri R, Bouzari H. (2006) Portal hypertension: contraindication to liver surgery? World J Surg 30:992-999.
89. Noguchi T, Kawarada Y, Kitagawa M, Ito F, Sakurai H, Machishi H et al. (1997) Clinicopathologic factors influencing the long-term prognosis following hepatic resection for large hepatocellular carcinoma more than 10 cm in diameter. Semin Oncol 24:S6-7-S6-13.
90. Regimbeau JM, Farges O, Shen BY, Sauvanet A, Belghiti J. (1999) Is surgery for large hepatocellular carcinoma justified? J Hepatol 31:1062-1068.
91. Bruix J, Llovet JM. (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519-524.
92. Young AL, Malik HZ, Abu-Hilal M, Guthrie JA, Wyatt J, Prasad KR et al. (2007) Large hepatocellular carcinoma: time to stop preoperative biopsy. J Am Coll Surg 205:453-462.
93. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA et al. (2005) Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 140:450-457; discussion 457-458.
94. Kosuge T, Makuuchi M, Takayama T, Yamamoto J, Shimada K, Yamasaki S. (1993) Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology 40:328-332.
95. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J et al. (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12:364-373.
96. Wang BW, Mok KT, Liu SI, Chou NH, Tsai CC, Chen IS et al. (2008) Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma? J Formos Med Assoc 107:616-626.
97. Poon RT, Fan ST. (2003) Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 12:35-50, viii.
98. Ikai I, Yamamoto Y, Yamamoto N, Terajima H, Hatano E, Shimahara Y et al. (2003) Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am 12:65-75.
99. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J et al. (2005) Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 137:403-410.